Cargando…
A host defense peptide mimetic, brilacidin, potentiates caspofungin antifungal activity against human pathogenic fungi
Fungal infections cause more than 1.5 million deaths a year. Due to emerging antifungal drug resistance, novel strategies are urgently needed to combat life-threatening fungal diseases. Here, we identify the host defense peptide mimetic, brilacidin (BRI) as a synergizer with caspofungin (CAS) agains...
Autores principales: | dos Reis, Thaila Fernanda, de Castro, Patrícia Alves, Bastos, Rafael Wesley, Pinzan, Camila Figueiredo, Souza, Pedro F. N., Ackloo, Suzanne, Hossain, Mohammad Anwar, Drewry, David Harold, Alkhazraji, Sondus, Ibrahim, Ashraf S., Jo, Hyunil, Lightfoot, Jorge D., Adams, Emily M., Fuller, Kevin K., deGrado, William F., Goldman, Gustavo H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10090755/ https://www.ncbi.nlm.nih.gov/pubmed/37045836 http://dx.doi.org/10.1038/s41467-023-37573-y |
Ejemplares similares
-
Brilacidin, a COVID‐19 drug candidate, demonstrates broad‐spectrum antiviral activity against human coronaviruses OC43, 229E, and NL63 through targeting both the virus and the host cell
por: Hu, Yanmei, et al.
Publicado: (2022) -
Phosphoproteomics of Aspergillus fumigatus Exposed to the Antifungal Drug Caspofungin
por: Mattos, Eliciane Cevolani, et al.
Publicado: (2020) -
Brilacidin Demonstrates Inhibition of SARS-CoV-2 in Cell Culture
por: Bakovic, Allison, et al.
Publicado: (2021) -
2393. Evaluation of Antifungal Treatment in a Neutropenic Mouse Model of Scedosporiosis
por: Alkhazraji, Sondus, et al.
Publicado: (2018) -
In Vitro Assessment of Antifungal Caspofungin on Leishmania donovani Culture Isolation
por: Bhattarai, Narayan Raj, et al.
Publicado: (2017)